EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity

Junryo Rii iD, Shinichi Sakamoto iD, Atsushi Mizokami, Minhui Xu, Ayumi Fujimoto, Shinpei Saito, Hidekazu Koike, Takaaki Tamura, Takayuki Arai, Yasutaka Yamada iD, Yusuke Goto, Tomokazu Sazuka und 5 weitere

Cancer Science · 2024

DOI: 10.1111/cas.16062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Junryo Rii und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. Hauptthemen laut MEDLINE: Large Neutral Amino Acid-Transporter 1, Prostatic Neoplasms, Benzoxazoles, Taxoids. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Grants-in-Aid for Scientific Research of the Ministry of Education, Culture, Sports, Science and Technology of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

L‐type amino acid transporter 1 (LAT1, SLC7A5 ) is an amino acid transporter expressed in various carcinomas, and it is postulated to play an important role in the proliferation of cancer cells through the uptake of essential amino acids. Cabazitaxel is a widely used anticancer drug for treating castration‐resistant prostate cancer (CRPC); however, its effectiveness is lost when cancer cells acquire drug resistance. In this study, we investigated the expression of LAT1 and the effects of a LAT1‐specific inhibitor, JPH203, in cabazitaxel‐resistant prostate cancer cells. LAT1 was more highly expressed in the cabazitaxel‐resistant strains than in the normal strains. Administration of JPH203 inhibited the growth, migration, and invasive ability of cabazitaxel‐resistant strains in vitro. Phosphoproteomics using liquid chromatography‐mass spectrometry to comprehensively investigate changes in phosphorylation due to JPH203 administration revealed that cell cycle‐related pathways were affected by JPH203, and that JPH203 significantly reduced the kinase activity of cyclin‐dependent kinases 1 and 2. Moreover, JPH203 inhibited the proliferation of cabazitaxel‐resistant cells in vivo. Taken together, the present study results suggest that LAT1 might be a valuable therapeutic target in cabazitaxel‐resistant prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Large Neutral Amino Acid-Transporter 1Prostatic NeoplasmsBenzoxazolesTaxoidsMaleHumansPhosphorylationCyclin-Dependent KinasesCell Line, TumorTyrosine

Stichwörter der Autor:innen

CDKLAT1amino acid transporterphosphoproteomicsprostate cancer

Substanzen

2-amino-3-(4-((5-amino-2-phenylbenzo(d)oxazol-7-yl)methoxy)-3,5-dichlorophenyl)propanoic acidcabazitaxelLarge Neutral Amino Acid-Transporter 1Cyclin-Dependent KinasesBenzoxazolesTyrosineTaxoids

Autor:innen und Institutionen

  • Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
  • Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
  • Bio-System Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.
  • Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan.

ORCID-Profile: Junryo Rii, Shinichi Sakamoto, Yasutaka Yamada, Yoshikatsu Kanai

Förderung

  • Grants-in-Aid for Scientific Research of the Ministry of Education, Culture, Sports, Science and Technology of Japan

Zitieren

APA

Rii, J., Sakamoto, S., Mizokami, A., Xu, M., Fujimoto, A., Saito, S., Koike, H., Tamura, T., Arai, T., Yamada, Y., Goto, Y., Sazuka, T., Imamura, Y., Suzuki, K., Kanai, Y., Anzai, N., & Ichikawa, T. (2024). L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity. Cancer Science. https://doi.org/10.1111/cas.16062

Vancouver

Rii J, Sakamoto S, Mizokami A, Xu M, Fujimoto A, Saito S, et al. L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity. Cancer Science. 2024. doi:10.1111/cas.16062

BibTeX
@article{Rii2024,
  author = {Rii, Junryo and Sakamoto, Shinichi and Mizokami, Atsushi and Xu, Minhui and Fujimoto, Ayumi and Saito, Shinpei and Koike, Hidekazu and Tamura, Takaaki and Arai, Takayuki and Yamada, Yasutaka and Goto, Yusuke and Sazuka, Tomokazu and Imamura, Yusuke and Suzuki, Kazuhiro and Kanai, Yoshikatsu and Anzai, Naohiko and Ichikawa, Tomohiko},
  title = {L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16062}
}
Kostenlos starten →